Ovid Therapeutics Inc.
OVID
$1.56
-$0.01-0.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -97.90% | 4,724.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -97.90% | 4,724.62% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -97.90% | 4,724.62% | |||
| SG&A Expenses | 39.04% | -18.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.55% | -10.53% | |||
| Operating Income | -146.86% | 59.58% | |||
| Income Before Tax | -159.56% | 54.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -159.56% | 54.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -159.56% | 54.24% | |||
| EBIT | -146.86% | 59.58% | |||
| EBITDA | -151.45% | 59.92% | |||
| EPS Basic | -164.30% | 54.31% | |||
| Normalized Basic EPS | -159.47% | 61.10% | |||
| EPS Diluted | -164.30% | 54.31% | |||
| Normalized Diluted EPS | -159.47% | 61.10% | |||
| Average Basic Shares Outstanding | 0.01% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||